Haematologica · 2025
Different features of acute myeloid leukemia stem cell quantification in intensively treated patients.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ngai Lok Lam, Reuvekamp Tom, Hanekamp Diana, Janssen Fleur, Marsbergen Laura Oudshoorn-van, Carbaat-Ham Jannemieke, Hofland Maaike A M, Fayed Mona M H E, Kelder Angèle, Scholten Willemijn J, Snel Alexander N, Bachas Costa, Tettero Jesse M, Breems Dimitri A, Fischer Thomas, Gjertsen Bjørn T, Griškevičius Laimonas, Juliusson Gunnar, Van de Loosdrecht Arjan A, Maertens Johan A, Manz Markus G, Pabst Thomas, Passweg Jakob R, Porkka Kimmo, Valk Peter J M, Gradowska Patrycja, Löwenberg Bob, Ossenkoppele Gert J, De Leeuw David C, Cloos Jacqueline
Аннотация
In acute myeloid leukemia, the burden of CD34+CD38- leukemia stem cells (LSC) has prognostic value at diagnosis and after induction chemotherapy. Since different methods of LSC quantification have been proposed, we determined the prognostic value on overall survival and incidence of relapse of these methods across European LeukemiaNet (ELN) 2017 risk groups, using data from the HOVON-SAKK132 trial. In addition, we evaluated the optimal number of acquired white blood cells for accurate LSC detection and the prognostic value of individual LSC markers. Results show that it is essential to acquire at least 1x106 white blood cells in order to assess LSC-negativity accurately. Among various LSC markers, CD44 overexpression on CD34+CD38- cells was the only marker that was not statistically significant in our panel. Testing the impact of several published variations of LSC analysis on prognostic value for overall survival and cumulative incidence of relapse showed only marginal differences, demonstrating the robust prognostic value of LSC burden. For further clinical implementation, the optimal LSC assessment may differ among ELN risk groups. In conclusion, LSC burden is a robust prognostic factor and insight into the different methods of LSC definition can facilitate the clinical implementation. Trial registration EudraCT Number: 2013-002843-26.